Meeting
2022 ASCO Genitourinary Cancers Symposium
Abiraterone decanoate (PRL-02): Pharmacology of a single intramuscular (IM) depot injection compared to oral abiraterone acetate (AA) in intact male rats.
Authors
William R. Moore
Propella Therapeutics, Pittsboro, NC
William R. Moore , Matthew Sharp , Joel Robert Eisner , Caroline Bell , Stuart Freeman , Tony Leesnitzer , Robert Schotzinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 160)
DOI
10.1200/JCO.2022.40.6_suppl.160
Abstract #
160
Poster Bd #
J3
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate in patients (pts) with advanced prostate cancer.
First Author: Jose W. Avitia
Poster
2021 ASCO Annual Meeting
A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).
First Author: Tim Warneke
Poster
2023 ASCO Annual Meeting
Phase 1/2a study of PRL-02, a long-acting intramuscular (IM) depot injection of abiraterone decanoate, in patients (pts) with advanced prostate cancer.
First Author: Neal D. Shore
Poster
2024 ASCO Genitourinary Cancers Symposium
The prognostic value of ductal adenocarcinoma of the prostate in patients with advanced prostate cancer treated with abiraterone acetate.
First Author: Yifu Shi